Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory

Area of Science:

• Hematology
• Infectious Diseases
• Clinical Pathology

Background:

• COVID-19 is linked to severe inflammation, hemostasis dysregulation, and increased thrombosis risk.
• Thromboembolic events occur frequently in COVID-19 patients, even with standard thromboprophylaxis.
• The effectiveness of current anticoagulation strategies and monitoring methods is questioned.

Purpose of the Study:

• To evaluate the role of various hemostasis tests in managing COVID-19.
• To discuss the limitations of current diagnostic and monitoring tools for COVID-19-associated coagulopathy.
• To explore the potential of specialized hemostasis assays for risk assessment and treatment monitoring.

Main Methods:

• Review of existing literature on hemostasis in COVID-19.
• Analysis of the utility and limitations of standard coagulation tests (aPTT, PT, fibrinogen, D-dimers).
• Evaluation of specialized hemostasis assays (e.g., viscoelastic tests, thrombin generation assays, soluble fibrin complexes, fibrinolysis tests).

Main Results:

• Standard hemostasis tests have significant drawbacks affecting reliability and clinical relevance in COVID-19.
• Specialized hemostasis tests may offer improved assessment of thrombotic risk in COVID-19.
• Monitoring unfractionated heparin in critically ill, inflamed COVID-19 patients presents unique laboratory challenges.

Conclusions:

• Current first-line hemostasis tests are insufficient for comprehensive management of COVID-19-related coagulopathy.
• Specialized hemostasis tests show promise for better risk stratification and monitoring in COVID-19.
• Further research is needed to optimize hemostasis testing strategies for COVID-19 patients.